Metabotropic glutamate receptors and their ligands applications in neurological and psychiatric disorders
author
Abstract:
Metabotropic glutamate receptors (mGluRs) consist of a large family of G-protein coupled receptors that are critical for regulating normal neuronal function in the central nervous system. The wide distribution and diverse physiological roles of various mGluR subtypes make them highly attractive targets for the treatment of a number of neurological and psychiatric disorders. The discovery of subtype selective ligands for these receptors has provided the tools to support a number of preclinical studies, suggesting the numerous therapeutic potential that lies in the ability selectively to modulate a specific mGluR subtype. mGluRs do not activate ion channels directly but instead through G-protiens activate second messenger mechanisms in the neurons. So far 8 subtypes of mGluRs have been identified which divided into three groups (Group I, II, and III) according to their sequence similarities, Signal transduction mechanisms and pharmacological properties. Depending on the receptor subtype, they might be localized at presynaptic or postsynaptic sites which regulate glutamate and other neurotransmitters release. As I applied many mGluR ligands on hippocampal slices and observed interesting results on synaptic transmission and modulation of certain neurotransmitters such as adenosine, I intended to study their application in neurological diseases. The method was based on my experiences from researches and different seminars to evaluate last decade development on mGluRs and their ligands application in certain neurological disorders. Therefore, aim of this review article is to describe mGluRs and their role in the excitotoxicity and neuroprotection. Then, application of different mGluR ligands for the treatment of a variety of neurological disorders including schizophrenia, Parkinson's disease, anxiety disorders, epilepsy, and drug abuse has been described.
similar resources
metabotropic glutamate receptors and their ligands applications in neurological and psychiatric disorders
metabotropic glutamate receptors (mglurs) consist of a large family of g-protein coupled receptors that are critical for regulating normal neuronal function in the central nervous system. the wide distribution and diverse physiological roles of various mglur subtypes make them highly attractive targets for the treatment of a number of neurological and psychiatric disorders. the discovery of sub...
full textIonotropic Glutamate Receptors and their Role in Neurological Diseases
Glutamate is extensively and relatively uniformly distributed in the central nervous system (CNS) and its effects mediated by two distinct groups of receptors including Ionotropic and metabotropic glutamate receptors. Concentration of glutamate in the nervous system is much higher than in other tissues. Glutamate receptors play an important role in synaptic transmission, neural plasticity and n...
full textMetabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders
Metabotropic glutamate receptors (mGlu receptors) have emerged as new therapeutic targets for psychiatric disorders, such as schizophrenia, depression and anxiety with their regulatory roles in glutamatergic transmissions. To date, several ligands selective for each mGlu receptor have been synthesized, and pharmacological significances of these ligands have been demonstrated in animal models. A...
full textGlutamate and psychiatric disorders
References http://apt.rcpsych.org/content/8/3/189#BIBL This article cites 0 articles, 0 of which you can access for free at: permissions Reprints/ [email protected] to To obtain reprints or permission to reproduce material from this paper, please write to this article at You can respond http://apt.rcpsych.org/cgi/eletter-submit/8/3/189 from Downloaded The Royal College of Psychiatrists ...
full textMy Resources
Journal title
volume 15 issue None
pages 72- 89
publication date 2011-04
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023